PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: PIPELINE ANALYSIS PART 07: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Steroid nasal sprays - Market size and forecast 2018-2023 Antibiotics - Market size and forecast 2018-2023 Decongestants - Market size and forecast 2018-2023 Other drugs - Market size and forecast 2018-2023 Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES Market drivers Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 14: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors CHIESI Farmaceutici Spa GlaxoSmithKline Plc Intersect ENT, Inc. Merck & Co., Inc. Sanofi PART 15: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Some key clinical trials for sinusitis and related comorbidities Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Steroid nasal sprays - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Steroid nasal sprays - Year-over-year growth 2019-2023 (%) Exhibit 22: Antibiotics - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Antibiotics - Year-over-year growth 2019-2023 (%) Exhibit 24: Decongestants - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Decongestants - Year-over-year growth 2019-2023 (%) Exhibit 26: Other drugs - Market size and forecast 2018-2023 ($ millions) Exhibit 27: Other drugs - Year-over-year growth 2019-2023 (%) Exhibit 28: Market opportunity by product Exhibit 29: Customer landscape Exhibit 30: Market share by geography 2018-2023 (%) Exhibit 31: Geographic comparison Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 33: North America - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in North America Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Europe - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Europe Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in Asia Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 42: ROW - Year-over-year growth 2019-2023 (%) Exhibit 43: Top 3 countries in ROW Exhibit 44: Key leading countries Exhibit 45: Market opportunity Exhibit 46: Impact of drivers and challenges Exhibit 47: Vendor landscape Exhibit 48: Landscape disruption Exhibit 49: Vendors covered Exhibit 50: Vendor classification Exhibit 51: Market positioning of vendors Exhibit 52: CHIESI Farmaceutici Spa - Vendor overview Exhibit 53: CHIESI Farmaceutici Spa - Business segments Exhibit 54: CHIESI Farmaceutici Spa - Organizational developments Exhibit 55: CHIESI Farmaceutici Spa - Geographic focus Exhibit 56: CHIESI Farmaceutici Spa - Segment focus Exhibit 57: CHIESI Farmaceutici Spa - Key offerings Exhibit 58: CHIESI Farmaceutici Spa - Key customers Exhibit 59: GlaxoSmithKline Plc - Vendor overview Exhibit 60: GlaxoSmithKline Plc - Business segments Exhibit 61: GlaxoSmithKline Plc - Organizational developments Exhibit 62: GlaxoSmithKline Plc - Geographic focus Exhibit 63: GlaxoSmithKline Plc - Segment focus Exhibit 64: GlaxoSmithKline Plc - Key offerings Exhibit 65: GlaxoSmithKline Plc - Key customers Exhibit 66: Intersect ENT Inc. - Vendor overview Exhibit 67: Intersect ENT Inc. - Business segments Exhibit 68: Intersect ENT Inc. - Organizational developments Exhibit 69: Intersect ENT Inc. - Key offerings Exhibit 70: Intersect ENT Inc. - Key customers Exhibit 71: Merck & Co. Inc. - Vendor overview Exhibit 72: Merck & Co. Inc. - Business segments Exhibit 73: Merck & Co. Inc. - Organizational developments Exhibit 74: Merck & Co. Inc. - Geographic focus Exhibit 75: Merck & Co. Inc. - Segment focus Exhibit 76: Merck & Co. Inc. - Key offerings Exhibit 77: Merck & Co. Inc. - Key customers Exhibit 78: Sanofi - Vendor overview Exhibit 79: Sanofi - Business segments Exhibit 80: Sanofi - Organizational developments Exhibit 81: Sanofi - Geographic focus Exhibit 82: Sanofi - Segment focus Exhibit 83: Sanofi - Key offerings Exhibit 84: Sanofi - Key customers Exhibit 85: Validation techniques employed for market sizing Exhibit 86: Definition of market positioning of vendors

CHIESI Farmaceutici Spa GlaxoSmithKline Plc Intersect ENT Inc. Merck & Co. Inc. Sanofi